These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 32193878)

  • 1. The Population Pharmacokinetics of Rifampicin in Japanese Pulmonary Tuberculosis Patients.
    Nishimura T; Kohno H; Nagai H; Maruoka D; Koike Y; Kobayashi M; Atsuda K
    Drug Res (Stuttg); 2020 May; 70(5):199-205. PubMed ID: 32193878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimization of dosing regimens of isoniazid and rifampicin in children with tuberculosis in India.
    Aruldhas BW; Hoglund RM; Ranjalkar J; Tarning J; Mathew SK; Verghese VP; Bose A; Mathew BS
    Br J Clin Pharmacol; 2019 Mar; 85(3):644-654. PubMed ID: 30588647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A simultaneous population pharmacokinetic analysis of rifampicin in Malawian adults and children.
    Schipani A; Pertinez H; Mlota R; Molyneux E; Lopez N; Dzinjalamala FK; van Oosterhout JJ; Ward SA; Khoo S; Davies G
    Br J Clin Pharmacol; 2016 Apr; 81(4):679-87. PubMed ID: 26613187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semimechanistic model to describe variable absorption.
    Wilkins JJ; Savic RM; Karlsson MO; Langdon G; McIlleron H; Pillai G; Smith PJ; Simonsson US
    Antimicrob Agents Chemother; 2008 Jun; 52(6):2138-48. PubMed ID: 18391026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Model-Based Evaluation of Higher Doses of Rifampin Using a Semimechanistic Model Incorporating Autoinduction and Saturation of Hepatic Extraction.
    Chirehwa MT; Rustomjee R; Mthiyane T; Onyebujoh P; Smith P; McIlleron H; Denti P
    Antimicrob Agents Chemother; 2016 Jan; 60(1):487-94. PubMed ID: 26552972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of isoniazid in pulmonary tuberculosis--a comparative study at two dose levels.
    Roy V; Tekur U; Chopra K
    Indian Pediatr; 1996 Apr; 33(4):287-91. PubMed ID: 8772902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Population Pharmacokinetic Model Incorporating Saturable Pharmacokinetics and Autoinduction for High Rifampicin Doses.
    Svensson RJ; Aarnoutse RE; Diacon AH; Dawson R; Gillespie SH; Boeree MJ; Simonsson USH
    Clin Pharmacol Ther; 2018 Apr; 103(4):674-683. PubMed ID: 28653479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intra-individual effects of food upon the pharmacokinetics of rifampicin and isoniazid.
    Requena-Méndez A; Davies G; Waterhouse D; Ardrey A; Jave O; López-Romero SL; Ward SA; Moore DAJ
    J Antimicrob Chemother; 2019 Feb; 74(2):416-424. PubMed ID: 30412245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Markers of gut dysfunction do not explain low rifampicin bioavailability in HIV-associated TB.
    Vinnard C; Ravimohan S; Tamuhla N; Pasipanodya J; Srivastava S; Modongo C; Zetola NM; Weissman D; Gumbo T; Bisson GP
    J Antimicrob Chemother; 2017 Jul; 72(7):2020-2027. PubMed ID: 28472448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetics of rifampicin and 25-deacetyl-rifampicin in healthy Asian adults.
    Seng KY; Hee KH; Soon GH; Chew N; Khoo SH; Lee LS
    J Antimicrob Chemother; 2015 Dec; 70(12):3298-306. PubMed ID: 26342028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV-1 Coinfection Does Not Reduce Exposure to Rifampin, Isoniazid, and Pyrazinamide in South African Tuberculosis Outpatients.
    Rockwood N; Meintjes G; Chirehwa M; Wiesner L; McIlleron H; Wilkinson RJ; Denti P
    Antimicrob Agents Chemother; 2016 Oct; 60(10):6050-9. PubMed ID: 27480859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A semimechanistic pharmacokinetic-enzyme turnover model for rifampin autoinduction in adult tuberculosis patients.
    Smythe W; Khandelwal A; Merle C; Rustomjee R; Gninafon M; Bocar Lo M; Sow OB; Olliaro PL; Lienhardt C; Horton J; Smith P; McIlleron H; Simonsson US
    Antimicrob Agents Chemother; 2012 Apr; 56(4):2091-8. PubMed ID: 22252827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of isoniazid in once-weekly rifapentine treatment of pulmonary tuberculosis.
    Mitchison DA
    Am J Respir Crit Care Med; 2003 May; 167(10):1298-9. PubMed ID: 12738593
    [No Abstract]   [Full Text] [Related]  

  • 14. Early phase evaluation of SQ109 alone and in combination with rifampicin in pulmonary TB patients.
    Heinrich N; Dawson R; du Bois J; Narunsky K; Horwith G; Phipps AJ; Nacy CA; Aarnoutse RE; Boeree MJ; Gillespie SH; Venter A; Henne S; Rachow A; Phillips PP; Hoelscher M; Diacon AH; ;
    J Antimicrob Chemother; 2015 May; 70(5):1558-66. PubMed ID: 25630641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A population approach of rifampicin pharmacogenetics and pharmacokinetics in Mexican patients with tuberculosis.
    Medellin-Garibay SE; Huerta-García AP; Rodríguez-Báez AS; Magaña-Aquino M; Ortiz-Álvarez A; Portales-Pérez DP; Milán-Segovia RDC; Romano-Moreno S
    Tuberculosis (Edinb); 2020 Sep; 124():101982. PubMed ID: 32810723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population pharmacokinetics of rifampicin in adult patients with osteoarticular infections: interaction with fusidic acid.
    Marsot A; Ménard A; Dupouey J; Muziotti C; Guilhaumou R; Blin O
    Br J Clin Pharmacol; 2017 May; 83(5):1039-1047. PubMed ID: 27813241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial.
    Ruslami R; Ganiem AR; Dian S; Apriani L; Achmad TH; van der Ven AJ; Borm G; Aarnoutse RE; van Crevel R
    Lancet Infect Dis; 2013 Jan; 13(1):27-35. PubMed ID: 23103177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population Pharmacokinetics of Rifampicin in Chinese Patients With Pulmonary Tuberculosis.
    Jing Y; Zhu LQ; Yang JW; Huang SP; Wang Q; Zhang J
    J Clin Pharmacol; 2016 May; 56(5):622-7. PubMed ID: 26387492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative bioavailability of rifampicin, isoniazid and pyrazinamide from a four drug fixed dose combination with separate formulations at the same dose levels.
    Agrawal S; Singh I; Kaur KJ; Bhade SR; Kaul CL; Panchagnula R
    Int J Pharm; 2004 May; 276(1-2):41-9. PubMed ID: 15113612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetics of rifampicin in Mexican patients with tuberculosis.
    Milán Segovia RC; Domínguez Ramírez AM; Jung Cook H; Magaña Aquino M; Vigna Pérez M; Brundage RC; Romano Moreno S
    J Clin Pharm Ther; 2013 Feb; 38(1):56-61. PubMed ID: 23167603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.